Apyx Medical CORP Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Apyx Medical Corporation Chief Operating Officer Shawn Roman exercised 15,000 stock options in a net settlement transaction.
NASDAQ
Director Wendy Levine was granted 50,000 stock options in Apyx Medical Corporation as part of an equity incentive.
NASDAQ
Director Stavros G. Vizirgianakis was granted 450,000 restricted stock units in Apyx Medical Corporation.
NASDAQ
Apyx Medical Corporation CEO Charles D. Goodwin II was granted 213,948 stock options as part of an equity incentive plan.
NASDAQ
Apyx Medical Corporation Chief Operating Officer Shawn David Roman was granted 88,044 stock options on June 11, 2026.
NASDAQ
Director Minnie Baylor-Henry was granted 50,000 stock options in Apyx Medical Corp as part of a standard equity incentive.
NASDAQ
Director Lawrence Waldman was granted 50,000 stock options in Apyx Medical Corporation as part of an equity incentive.
NASDAQ
Apyx Medical Corporation CFO Matthew C. Hill was granted 132,066 stock options as part of an equity incentive plan.
NASDAQ
Moshe Citronowicz, Sr. V.P. of Operations at Apyx Medical, was granted 63,392 stock options exercisable at $4.65 per share.
NASDAQ
Apyx Medical Corporation's Senior Vice President, Moshe Citronowicz, exercised options to acquire 37,000 shares of common stock at $1.80 per share.
NASDAQ
Apyx Medical's Chief Operating Officer, Shawn David Roman, exercised stock options to acquire 12,000 shares of common stock at $1.80 per share.
NASDAQ
Matthew C. Hill, CFO of Apyx Medical Corp, reports the acquisition of stock options.
NASDAQ
Moshe Citronowicz, Sr. V.P. of Operations at Apyx Medical Corp, was granted stock options to purchase 36,000 shares of common stock.
NASDAQ
Lawrence Waldman, a director at Apyx Medical Corp, was granted stock options to purchase 30,000 shares of common stock.
NASDAQ
Director Minnie Baylor-Henry of Apyx Medical Corp was granted stock options on May 15, 2025.
NASDAQ
Director Stavros G. Vizirgianakis acquired stock options in Apyx Medical Corp on May 15, 2025.
NASDAQ
Charles D. Goodwin II, CEO of Apyx Medical Corp, reports the acquisition of stock options.
NASDAQ
Director Wendy Levine of Apyx Medical Corp reports the grant of a stock option.
NASDAQ
Matthew C. Hill, CFO of Apyx Medical Corp, amends a previous Form 4 filing to include an additional purchase of 664 shares of common stock.
NASDAQ
Shawn David Roman, Chief Operating Officer of Apyx Medical Corp, was granted stock options for 100,000 shares on January 15, 2025.
NASDAQ
Charles D. Goodwin II, CEO of Apyx Medical Corp, reports the acquisition of 50,000 stock options on January 15, 2025.
NASDAQ
Director Minnie Baylor-Henry acquired 50,000 stock options in Apyx Medical Corp on January 15, 2025, as part of the Director Compensation Program.
NASDAQ
Apyx Medical Corp's CFO, Matthew C. Hill, was granted stock options on January 15, 2025, according to a Form 4 filing with the SEC.
NASDAQ
Director Wendy Levine acquired 50,000 stock options in Apyx Medical Corp as part of the Director Compensation Program.
NASDAQ
Director Stavros G. Vizirgianakis acquired 50,000 stock options in Apyx Medical Corp under the company's Director Compensation Program.
NASDAQ
Director Lawrence Waldman acquired 50,000 stock options in Apyx Medical Corp on January 15, 2025, as part of the Director Compensation Program.
NASDAQ
Moshe Citronowicz, Sr. V.P. of Operations at Apyx Medical Corp, was granted stock options for 36,000 shares on January 15, 2025.
NASDAQ
Matthew C. Hill, CFO of Apyx Medical Corp, purchased 5,336 shares of common stock at an average price of $1.13 on August 13, 2024.
NASDAQ
Director Lawrence Waldman acquired 17,000 stock options in Apyx Medical Corp on August 8, 2024, as part of the Director Compensation Program.
NASDAQ
Director Craig A. Swandal acquired 17,000 stock options in Apyx Medical Corp on August 8, 2024, as part of the Director Compensation Program.